Erratum: Antitumor activities of agonistic anti-TNFR antibodies require differential FcγRIIB coengagement in vivo (Proceedings of the National Academy of Sciences of the United States of America (2013) 110 (19501-19506) DOI:10.1073/pnas.1319502110);Antitumor activities of agonistic anti-TNFR antibodies require differential FcγRIIB coengagement in vivo

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 48, 2013, Pages 19501-19506

  Li, Fubin ^a,b   Ravetch, Jeffrey V ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Anti CD40; Anti DR5; Fc engineering; ITAM; ITIM

Indexed keywords

ANTINEOPLASTIC AGENT; FC RECEPTOR IIB; PROTEIN ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL POPULATION; CONTROLLED STUDY; CROSS LINKING; GENE MUTATION; GENETIC ANALYSIS; IMMUNOCOMPETENT CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 84888357068     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1407161111     Document Type: Erratum

References (26)

1. Muta T, et al. (1994) A 13-amino-acid motif in the cytoplasmic domain of Fc gamma RIIB modulates B-cell receptor signalling. Nature 369(6478):340.
2. Daëron M, et al. (1995) The same tyrosine-based inhibition motif, in the intracytoplasmic domain of Fc gamma RIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation. Immunity 3(5): 635-646.
3. Dhodapkar KM, et al. (2007) Selective blockade of the inhibitory Fcgamma receptor (FcgammaRIIB) in human dendritic cells and monocytes induces a type I interferon response program. J Exp Med 204(6): 1359-1369.
4. Dhodapkar KM, et al. (2005) Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. Proc Natl Acad Sci USA 102(8): 2910-2915.
5. Nimmerjahn F, Ravetch JV (2008) Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 8(1): 34-47.
6. Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6(4): 443-446.
7. Weng WK, Levy R (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21(21): 3940-3947.
8. Cartron G, et al. (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99(3): 754-758.
9. Musolino A, et al. (2008) Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 26(11): 1789-1796.
10. Simpson TR, et al. (2013) Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 210(9): 1695-1710.
11. Bulliard Y, et al. (2013) Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med 210(9): 1685-1693.
12. Nimmerjahn F, Ravetch JV (2005) Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science 310(5753): 1510-1512.
13. Grewal IS, ed (2009) Therapeutic Targets of the TNF Superfamily (Springer, New York), pp 1-220.
14. Li F, Ravetch JV (2011) Inhibitory Fcγ receptor engagement drives adjuvant and antitumor activities of agonistic CD40 antibodies. Science 333(6045): 1030-1034.
15. Li F, Ravetch JV (2012) Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement. Proc Natl Acad Sci USA 109(27): 10966-10971.
16. White AL, et al. (2011) Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J Immunol 187(4): 1754-1763.
17. Xu Y, et al. (2003) Fc gamma Rs modulate cytotoxicity of anti-Fas antibodies: Implications for agonistic antibody-based therapeutics. J Immunol 171(2): 562-568.
18. Wilson NS, et al. (2011) An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell 19(1): 101-113.
19. Li F, Ravetch JV (2012) A general requirement for FcγRIIB co-engagement of agonistic anti-TNFR antibodies. Cell Cycle 11(18): 3343-3344.
20. Daëron M (1995) Intracytoplasmic sequences involved in the biological properties of low-affinity receptors for IgG expressed by murine macrophages. Braz J Med Biol Res 28(3): 263-274.
21. Ono M, Bolland S, Tempst P, Ravetch JV (1996) Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor Fc(gamma)RIIB. Nature 383(6597): 263-266.
22. Liu Q, et al. (1998) The inositol polyphosphate 5-phosphatase Ship is a crucial negative regulator of B cell antigen receptor signaling. J Exp Med 188(7): 1333-1342.
23. Fong DC, et al. (2000) Mutational analysis reveals multiple distinct sites within Fc gamma receptor IIB that function in inhibitory signaling. J Immunol 165(8): 4453-4462.
24. Takeda K, et al. (2008) Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease. Proc Natl Acad Sci USA 105(31): 10895-10900.
25. Racanelli V, Rehermann B (2006) The liver as an immunological organ. Hepatology 43(Suppl 1):S54-S62.
26. Takeda K, et al. (2004) Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med 199(4): 437-448.